Uygur Medicine Xipayi Kui Jie’an Affects Gene Expression profiles in intestinal tissue Lesions in a Rat Model of Ulcerative Colitis

BMC Complementary and Alternative Medicine

Halmurat Upur¹  Mairipaiti Abudula²  Ajiguli Nuermaimaiti²  Gulinisha Mosha²  Li Zhong²  Jingping Zhang²  Kurexi Yunusi² 

[1] Traditional Uighur Medicine Institute, Xinjiang Medical University, Urumqi 830000, Xinjiang, China;Department of Molecular Biology and Biochemistry, College of Basic Medicine, Xinjiang Medical University, Urumqi 830000, Xinjiang, China

关键词: Microarray;    Immunity and inflammation;    Xipayi kuijie’an;    Ulcerative colitis;    Uygur Medicine;   

Others  :  1205854
DOI  :  10.1186/s12906-015-0672-x

 received in 2014-10-28, accepted in 2015-05-13,  发布年份 2015

【 摘 要 】

Background

The aim of this study was to investigate the mechanisms underlying the therapeutic effect of Uygur medicine KJA on UC in a rat model.

Methods

UC was induced in Wistar rats by application of 2, 4-dinitrochlorobenzene and acetic acid and were then treated with three different doses of KJA, and normal saline as control. After treatment for 20 days, the gene expression profile of colonic tissue was analyzed by microarray and verified by quantitative real-time RT-PCR.

Results

Animals treated with the three different doses of KJA were compared with normal saline controls, wherein microarray analysis identified 1991, 2163, and 1677 differentially expressed genes respectively, of which 444 genes were raised and 670 genes were decrease spliced together in the three doses tested. The KEGG pathway analyses found commonly raised genes related to several different biological functions. Interesting genes included TRL2, IL-1β, TGF-β1, and NF-κB were confirmed by quantitative PCR.

Conclusions

The therapeutic effect of KJA on UC is likely explained by specific effects on the expression of genes, which are the effector molecules known to be involved in the development of UC. Further studies on differentially expressed genes will help explain the mechanism of action of Uygur medicine KJA.

【 授权许可】

   
2015 Yunusi et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun. 2006; 50:147-50.
• [2]Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006; 12:6102-8.
• [3]Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J. 2006; 82:332-7.
• [4]Sclano G. Asthma, nasal polyposis and ulcerative colitis: a new perspective. Clin Exp Allergy. 2002; 32:1144-9.
• [5]Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001; 120:622-35.
• [6]Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al.. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-76.
• [7]Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB et al.. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012; 18:201-11.
• [8]Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448:427-34.
• [9]Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013; 62:1505-10.
• [10]Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000; 95:1263-76.
• [11]Daperno M, Sostegni R, Rocca R, Rigazio C, Scaglione N, Castellino F et al.. Medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther. 2002; 16:7-12.
• [12]Löfberg R. Medical treatment of mild to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2003; 17:18-22.
• [13]Scribano M, Prantera C. Medical treatment of moderate to severe Crohn’s disease. Aliment Pharmacol Ther. 2003; 17:23-30.
• [14]Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A et al.. Maintenance treatment of Crohn’s disease. Aliment Pharmacol Ther. 2003; 17:31-7.
• [15]Cottone M, Orlando A, Viscido A, Calabrese E, Camma C, Casa A. Prevention of postsurgical relapse and recurrence in Crohn’s disease. Aliment Pharmacol Ther. 2003; 17:38-42.
• [16]Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut. 2002; 50:iii43-6.
• [17]Michelassi F, Stella M, Block GE. Prospective assessment of functional results after ileal J pouch—anal restorative proctocolectomy. Arch Surg. 1993; 128:889-95.
• [18]Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World journal of gastroenterology: WJG. 2008; 14:3937-47.
• [19]Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P et al.. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80 + CD11bhighGr1low macrophages. J Clin Invest. 2011; 121:1692-708.
• [20]Drug Standards of the Ministry of Public Health of the People’s Republic of China. Book Drug Standards of the Ministry of Public Health of the People’s Republic of China. Uygur Pharmaceutical Section, City; 1998.
• [21]Iminjan M, Yunus K, Hizbilla M, Hupur H, Li Y. Experimental Study of Effects of Uygur Medicine Xipayi Kuijie’an on Colon Mucosa Apoptosis and the Mechanism of Treating Ulcerative Colitis. Keji Daobao/ Science & Technology Review. 2011; 29:29-35.
• [22]Guo Xia YK, Kerim A. Effect of Uyghur compound Xipayi KuiJie’an on the ultrastructure of small intestinal epithelial cell in Rat Model of Ulcerative Colitis. Journal of Xinjiang Medical University. 2009; 32:893-5.
• [23]Upur H, Yunus K, Mijiti Y, Huang JJ, He J, Lian JJ. The histologic effects of the Uyghur medicine xipayi kuijiean on ulcerative colitis in rats. JATMS. 2011; 17:219-23.
• [24]Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu T-M, Bao W et al.. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol. 2006; 24:1140-50.
• [25]Guo Y, Guo H, Zhang L, Xie H, Zhao X, Wang F et al.. Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells. J Virol. 2005; 79:14392-403.
• [26]Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J et al.. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002; 30:e15-e15.
• [27]Ding L, Hao F, Shi Z, Wang Y, Zhang H, Tang H et al.. Systems biological responses to chronic perfluorododecanoic acid exposure by integrated metabonomic and transcriptomic studies. J Proteome Res. 2009; 8:2882-91.
• [28]Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 2001; 29:e45-e45.
• [29]Műzes G, Molnár B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World journal of gastroenterology: WJG. 2012; 18:5848-61.
• [30]Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. Journal of Histochemistry & Cytochemistry. 2008; 56:267-74.
• [31]Low D, Nguyen DD, Mizoguchi E. Animal models of ulcerative colitis and their application in drug research. Drug design, development and therapy. 2013; 7:1341-57.
• [32]Kim S, Karin M. Role of TLR2‐dependent inflammation in metastatic progression. Ann N Y Acad Sci. 2011; 1217:191-206.
• [33]Curtiss L, Tobias P. The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets. 2007; 8:1230-8.
• [34]Muzio M, Polentarutti N, Bosisio D, Manoj KP, Mantovani A. Toll-like receptor family and signalling pathway. Biochem Soc Trans. 2000; 28:563-6.
• [35]Candia E, Díaz-Jiménez D, Langjahr P, Núñez LE, de la Fuente M, Farfán N et al.. Increased production of soluble TLR2 by lamina propria mononuclear cells from ulcerative colitis patients. Immunobiology. 2012; 217:634-42.
• [36]Dinarello C. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002; 20:S1-13.
• [37]Lee HS, Song CY. Effects of TGF-β on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press Res. 2010; 33:24-9.
• [38]Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol. 2009; 9:447-53.
• [39]Salib R, Howarth P. Transforming growth factor‐β in allergic inflammatory disease of the upper airways: friend or foe? Clinical & Experimental Allergy. 2009; 39:1128-35.
• [40]Liberek A, Kmieć Z, Kartanowicz D, Wierzbicki PM, Stanisławowski M, Kaszubowska L et al.. The mRNA level of the transforming growth factor β1 gene, but not the amount of the gene product, can be considered as a potential prognostic parameter in inflammatory bowel diseases in children. Int J Color Dis. 2013; 28:165-72.
• [41]Stadnicki A, Machnik G, Klimacka-Nawrot E, Wolanska-Karut A, Labuzek K. Transforming growth factor-β1 and its receptors in patients with ulcerative colitis. Int Immunopharmacol. 2009; 9:761-6.
• [42]Song MG, Hong BT, Lian SB, Wei Y. Effect of traditional Chinese medicinal enemas on ulcerative colitis of rats. World J Gastroenterol. 2004; 10:1914-7.
• [43]Fan H, Qiu MY, Mei JJ, Shen GX, Liu SL, Chen R. Effects of four regulating-intestine prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J Gastroenterol. 2005; 11:4800-6.